<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03837444</url>
  </required_header>
  <id_info>
    <org_study_id>D20180152</org_study_id>
    <nct_id>NCT03837444</nct_id>
  </id_info>
  <brief_title>Microvesicles and Monocytes to Predict Mortality of Patients With Cirrhosis</brief_title>
  <acronym>PROMICE</acronym>
  <official_title>Microvesicles and Monocytes to Predict Mortality of Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic liver diseases related to viral hepatitis, metabolic syndrome or excessive alcohol&#xD;
      consumption can evolve towards cirrhosis. Cirrhosis is responsible for 170 000 deaths per&#xD;
      year in Europe. Initially asymptomatic and called &quot;compensated&quot; it can become &quot;decompensated&quot;&#xD;
      with the developement of acute complications such as infections, ascites or variceal&#xD;
      bleeding. The transition from compensated to decompensated cirrhosis is associated with a&#xD;
      reduction in survival from 95 to 55% at 1 year.&#xD;
&#xD;
      The only curative treatment for cirrhosis is liver transplantation (LT). Liver transplants&#xD;
      are allocated according to the severity of the patients. Despite a modest prognostic value&#xD;
      (area under the ROC curve = 0.7 to predict the risk of death), graft allocation is based on&#xD;
      the MELD (Model for End-Stage Liver Disease) score including INR, bilirubin and serum&#xD;
      creatinine. In 2014, 11.5% of registered patients died on the liver transplant waiting list,&#xD;
      illustrating the need for biomarkers that predict death and improve MELD-based prediction.&#xD;
&#xD;
      Microvesicles are membrane vesicles released in extracellular space during cell activation or&#xD;
      apoptosis. Our team showed that circulating levels of hepatocyte microvesicles increase with&#xD;
      the severity of cirrhosis and predict survival at 6 months independently of MELD score in a&#xD;
      cohort of 242 patients with cirrhosis.&#xD;
&#xD;
      Type 1 interferons (IFN-1) are mediators of inflammation, which is excessively activated in&#xD;
      cirrhosis. Our team has shown that a gene signature (IFN score) measured in the immune cells&#xD;
      of 101 patients with cirrhosis is able to predict 6 month-survival independently of the MELD&#xD;
      score.&#xD;
&#xD;
      Thus, the investigators hypothesize that a composite score combining the level of circulating&#xD;
      hepatocyte microvesicles, the IFN score and the MELD score could improve the prediction of&#xD;
      survival in patients with severe cirrhosis.&#xD;
&#xD;
      The aim of this study is to compare the prognostic performance for the cumulative incidence&#xD;
      of death at 6 months of a composite score including MELD, hepatocyte microvesicle level and&#xD;
      IFN score with that of the MELD score alone, in patients with Child B or C cirrhosis,&#xD;
      considering liver transplantation as a competitive risk.&#xD;
&#xD;
      To address this question, peripheral blood from 335 patients with Child B or C cirrhosis will&#xD;
      be obtained and hepatocyte microvesicle levels and IFN score will be measured using&#xD;
      ELISA/filtration and Real Time-quantitative PCR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Natural history of cirrhosis&#xD;
&#xD;
      Cirrhosis is the end stage form of chronic liver disease. It is estimated that 200,000 to&#xD;
      500,000 people in France have cirrhosis. Cirrhosis is responsible for more than 170,000&#xD;
      deaths per year in Europe.&#xD;
&#xD;
      The main causes of cirrhosis include excessive alcohol consumption, the leading cause in&#xD;
      Europe, and chronic viral hepatitis B and C, which are the leading causes in Asia and Africa.&#xD;
      In addition, the current epidemic of obesity and type 2 diabetes worldwide has led to a sharp&#xD;
      increase in the incidence of non-alcoholic steatohepatitis associated with metabolic&#xD;
      syndrome, particularly in North America.&#xD;
&#xD;
      Cirrhosis is defined histologically as a diffuse alteration in the architecture of the liver&#xD;
      by annular fibrosis associated with regeneration nodules. With the emergence of non-invasive&#xD;
      tests allowing fibrosis measurement, cirrhosis is now considered highly probable when the&#xD;
      liver elasticity measured by Fibroscan® is &gt; 15 kPa.&#xD;
&#xD;
      Patients with cirrhosis may be perfectly asymptomatic and have normal liver function. In this&#xD;
      case, the Child-Pugh score, which rates the severity of cirrhosis, is &quot;A&quot;. However, the&#xD;
      severity of cirrhosis may increase, resulting in the development of signs of liver failure,&#xD;
      such as jaundice, decreased coagulation factors and hypoalbuminemia, and/or ascites or&#xD;
      hepatic encephalopathy. Cirrhosis is then classified as Child-Pugh B or C.&#xD;
&#xD;
      The progression of cirrhosis involves various processes: on the one hand, a slow and&#xD;
      continuous worsening associated with the persistence of hepatic aggression by one or more&#xD;
      causal agents (alcohol and/or metabolic syndrome and/or virus) and on the other hand, rapid&#xD;
      worsening occurring with acute complications of the disease such as variceal bleeding or&#xD;
      bacterial infections. Indeed, cirrhosis is associated with major alterations in innate&#xD;
      immunity that promote severe bacterial infections, which can lead to organ failure. Such a&#xD;
      complication represents a turning point in the natural history of cirrhosis since the&#xD;
      transition from compensated to decompensated cirrhosis is associated with a reduction in&#xD;
      1-year survival from 95 to 60%. When these complications are associated with organ failure,&#xD;
      short term mortality is dramatically increased with one-third of patients dying within one&#xD;
      month. The association of acute decompensation of cirrhosis with one or more organ failures&#xD;
      has recently been defined as a new syndrome named Acute-on-Chronic Liver Failure (ACLF).&#xD;
&#xD;
      The only curative treatment for cirrhosis is liver transplantation (LT). However, each year,&#xD;
      between 10 and 15% of patients on the French liver transplant waiting list cannot access&#xD;
      transplant and die prematurely from an acute complication of cirrhosis. In addition, many&#xD;
      patients die before they are even put on the transplant waiting list, as evidenced by the&#xD;
      results of a recent French multicenter study showing that the 6-month mortality rate for&#xD;
      patients with decompensated cirrhosis, Child C, remains equal to 25%[8].&#xD;
&#xD;
      Predicting of the outcome is therefore a major challenge in the management of cirrhotic&#xD;
      patients.&#xD;
&#xD;
      Prediction of the outcome of patients with cirrhosis: clinical scores.&#xD;
&#xD;
      Currently, prediction of the outcome of cirrhotic patients is based on the MELD (Model for&#xD;
      End-Stage Liver Disease) score. MELD score includes three objective laboratory criteria (INR,&#xD;
      serum bilirubin and serum creatinine). It was established in 2000 in an American cohort to&#xD;
      predict the risk of death at 3 months after TIPS placement (Transjugular Intrahepatic&#xD;
      Portosystemic Shunt). Its use was very quickly extended to the prediction 3-month survival of&#xD;
      cirrhotic patients on the transplant waiting list. Since 2007, in France, graft allocation&#xD;
      has been based on the MELD score, with patients with the highest score being transplanted&#xD;
      first.&#xD;
&#xD;
      Since that time, the predictive value of MELD has been studied in large cohorts, showing that&#xD;
      MELD's performance in predicting death is modest, with areas under the ROC curves (AUROC)&#xD;
      ranging from 0.64 to 0.72[3, 7, 19, 20]. In 2014, 7 years after the introduction of the MELD&#xD;
      score, it was found that 11.5% of patients on the liver transplant waiting list still died&#xD;
      before they could be transplanted. These data illustrate the need to improve our ability to&#xD;
      predict death of patients with advanced cirrhosis.&#xD;
&#xD;
      In this perspective, some authors have tried to improve the MELD score by adding one or more&#xD;
      variables, such as serum sodium (MELD-Na=MELD-Na-[0.025×MELD× (140 - Na)] + 140). The&#xD;
      contribution of these modified MELD scores was not considered sufficient to promote their use&#xD;
      in clinical practice, leaving the objective of improving MELD unmet.&#xD;
&#xD;
      Prediction of the outcome of patients with cirrhosis: novel biomarkers&#xD;
&#xD;
      Beside clinical scores, some biomarkers look promising. Indeed, as part of the close&#xD;
      collaboration between the clinical departments of Beaujon Hospital (Hepatology and&#xD;
      Anesthesia-Resuscitation) and the Inserm teams (Dr E Weiss, Dr R Moreau, Inserm U1149, Centre&#xD;
      de recherche sur l'inflammation, Paris) and Pr PE Rautou, Dr C Boulanger, Inserm U970 ;&#xD;
      Centre de recherche cardiovasculaire, Paris), two types of biomarkers have recently been&#xD;
      identified that predict the survival of patients with cirrhosis.&#xD;
&#xD;
      Microvesicles are vesicles released into the extracellular medium during cell activation or&#xD;
      apoptosis, two phenomena strongly involved in cirrhosis. The Inserm U970 team (Pr PE Rautou,&#xD;
      Dr C Boulanger) showed in 2012 that the circulating concentrations of hepatocyte&#xD;
      microvesicles increase with the severity of cirrhosis. In addition, microvesicles in patients&#xD;
      with child B or C cirrhosis promote portal hypertension by inducing arterial hyporeactivity&#xD;
      to vasoconstrictive agents. Based on these results, a prospective study including 242&#xD;
      patients with cirrhosis showed that circulating concentrations of hepatocyte microvesicles&#xD;
      are able to predict the survival at 6 months of patients with cirrhosis independently of the&#xD;
      MELD score.&#xD;
&#xD;
      The susceptibility of cirrhotic patients to severe infections is related to abnormalities in&#xD;
      their innate immune response and in particular to the occurrence of an excessive inflammatory&#xD;
      response, responsible for organ failure. Type 1 interferons (IFN 1) are inflammatory&#xD;
      mediators whose impact on the prognosis of sepsis could be harmful. To determine whether type&#xD;
      1 IFN pathway activity was involved in the innate immune response deregulation and in the&#xD;
      susceptibility to sepsis of patients with cirrhosis, the Inserm U1149 team measured, using&#xD;
      Real-Time quantitative PCR, a gene signature (IFN score) reflecting the activation of this&#xD;
      pathway in the immune cells of 99 patients with decompensated cirrhosis hospitalized at the&#xD;
      liver department at Beaujon Hospital. The investigators have thus shown that the IFN score is&#xD;
      able to predict the risk of death of cirrhotic patients independently of the MELD score with&#xD;
      AUROC equal to 0.79 (0.7 for MELD).&#xD;
&#xD;
      It should be noted that these two biomarkers (hepatocyte microvesicles and IFN score) reflect&#xD;
      different and complementary pathophysiological processes: hepatocyte microvesicles reflect&#xD;
      persistent liver injury while IFN score reflects innate immune response. It should also be&#xD;
      noted that these biomarkers, protected by two international patents (EP121528133.5 and&#xD;
      EP2016/077129) can be measured on peripheral blood using simple and readily available&#xD;
      techniques (ELISA/filtration, qPCR).&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
      In this project, the investigators hypothesize that prediction of death of patients with&#xD;
      advanced cirrhosis (Child-Pugh B or C) by a composite score combining circulating&#xD;
      concentrations of hepatocyte microvesicles, IFN score and MELD score will be better than that&#xD;
      assessed using the MELD score alone.&#xD;
&#xD;
      This composite score will help physicians to judge the emergency of liver transplantation and&#xD;
      thus to refine criteria for the allocation of liver transplants. This composite score may&#xD;
      also identify a patient population at particular risk of death that should be subjected to&#xD;
      increased surveillance while waiting for liver transplantation. Through these two approaches&#xD;
      (better prioritization of patients for liver transplantation and increased monitoring of&#xD;
      high-risk patients), this new composite score will reduce mortality in cirrhosis patients&#xD;
      waiting for liver transplantation.&#xD;
&#xD;
      Finally, new therapeutic approaches to improve survival of patients with severe cirrhosis&#xD;
      awaiting liver transplantation (e. g. by reducing the occurrence of complications) are&#xD;
      regularly tested. The composite score the investigators propose could also be used as a&#xD;
      &quot;companion&quot; to monitor the effectiveness of these new treatments.&#xD;
&#xD;
      Population&#xD;
&#xD;
      Patients with Child-Pugh B or C cirrhosis (proven by liver biopsy, by non invasive method of&#xD;
      fibrosis quantification or by a combination of clinical, biological and radiological signs,&#xD;
      see above) will be included during a two-year period.&#xD;
&#xD;
      Patients will be included during follow-up outpatient visits in hepatology or during&#xD;
      scheduled hospitalization for example for digestive endoscopy to screen signs of portal&#xD;
      hypertension or for ascites removal. They will therefore be in a stable condition.&#xD;
&#xD;
      Presence of acute events or events that may modify the risk of death or liver&#xD;
      transplantation, and/or the inflammatory response or release of microvesicles will be among&#xD;
      non-inclusion criteria (see above).&#xD;
&#xD;
      Biomarker measurements&#xD;
&#xD;
      After informed consent, fifteen to twenty milliliters of peripheral venous blood (3 EDTA&#xD;
      tubes and 3 citrate tubes) will be collected from patients participating in the study&#xD;
&#xD;
      For hepatocyte microvesicles, citrated tubes will be centrifuged twice and then frozen at&#xD;
      -80°C until analysis.&#xD;
&#xD;
      For the IFN score, blood contained in the 3 EDTA tubes will be used to isolate Peripheral&#xD;
      Blood Mononuclear Cells (PBMCs). PBMCs will be lysed to obtain RNA that will be stored at&#xD;
      -80°C until the IFN score is measured.&#xD;
&#xD;
      At the end of the 2-year inclusion period, measurements of hepatocyte microvesicles and IFN&#xD;
      score will be performed for all patients during a 1-year period. Plasma concentrations of&#xD;
      hepatocyte microvesicles will be determined on platelet-free plasma using ELISA/filtration.&#xD;
      To measure IFN score, RNA from previously isolated PBMCs will first be reverse transcribed.&#xD;
      Then, the expression of five mRNAs of interest will be measure to calculate the IFN score.&#xD;
&#xD;
      Primary endpoint&#xD;
&#xD;
      The primary endpoint is the area under the ROC curve of the composite score including MELD,&#xD;
      hepatocyte microvesicle concentration and IFN score for predicting the cumulative incidence&#xD;
      of death at 6 months (considering liver transplantation as a competitive risk) compared to&#xD;
      the area under the ROC curve of the MELD score alone.&#xD;
&#xD;
      Measurement of the primary endpoint will be performed according to the recommendations&#xD;
      specific for survival analysis in patients with cirrhosis, using a survival analysis that&#xD;
      considers liver transplantation as a competitive risk. Data from patients who did not die or&#xD;
      have not been transplanted will be censored at the end of follow-up or on the date of last&#xD;
      news (if the patient is lost to follow-up) or at the date of termination of participation (in&#xD;
      the event of termination of participation). Follow-up period will be one year after inclusion&#xD;
      (maximum 13 months for patients who have been transplanted in the 12th month after&#xD;
      inclusion). A follow-up visit 6 and 12 months after inclusion will be scheduled. Data on&#xD;
      possible deaths or transplants will be obtained during this visit, using medical records, or&#xD;
      following telephone calls to patients or their relatives. For subjects who are lost to&#xD;
      follow-up, requests will be made to the CépiDc to obtain their vital status. Data concerning&#xD;
      possible transplants will be obtained via a request for access to the &quot;Cristal&quot; database&#xD;
      (https://www.sipg.sante.fr) developed by the Agence de la biomédecine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death at 6 months of a composite score including MELD, hepatocyte microvesicle concentration and IFN score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting the cumulative incidence of death at 6 months (considering liver transplantation (LT) as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death at 12 months of a composite MELD-microvesicles-IFN score to that of the MELD alone, considering liver transplantation as a competitive risk</measure>
    <time_frame>12 months</time_frame>
    <description>AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting the cumulative incidence of death at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death post-LT, of the composite MELD-microvesicles-IFN score to that of the MELD alone, in patients with Child B or C cirrhosis transplanted during the 12 months following the inclusion</measure>
    <time_frame>One month post LT</time_frame>
    <description>AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting survival at 1 month post-LT in patients transplanted within 12 months of their inclusion compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for episodes of &quot;Acute on Chronic Liver Failure&quot;, of the composite MELD-microvesicles-IFN score to the MELD score alone, considering LT and death as competitive risks at 6 and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>AUROC of the composite score for predicting the occurrence of episodes of &quot;Acute on Chronic Liver Failure&quot; at 6 and 12 months of inclusion, considering LT and death as competitive risks compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether this composite score improves prediction of the cumulative incidence of death of patients with Child B or C cirrhosis, compared to the MELD score alone, using the continuous version of the Net Reclassification Index (NRI)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>NRI measuring the reclassification improvement of the composite score for predicting the cumulative incidence of death at 6 and 12 months in patients with Child B or C cirrhosis compared to the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death of a MELD-microvesicles-IFN score to that of the MELD-Na score, considering LT as a competitive event at 6 and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>AUROC of the composite score for predicting cumulative incidence of death at 6 and 12 months (considering LT as a competitive risk), compared to the AUROC of the MELD-Na score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death of a composite MELD-hepatocyte microvesicles score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the composite score including MELD and hepatocyte microvesicle for predicting the cumulative incidence of death at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death of a composite MELD-IFN score with that of the MELD score alone, considering liver transplantation as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the composite score including MELD and IFN score for predicting the cumulative incidence of death at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence death due to infection of the composite MELD-microvesicles-IFN score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the score including MELD, microvesicles and IFN score for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles-IFN score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>12 months</time_frame>
    <description>AUROC of the score including MELD, microvesicles and IFN score for the prediction of the cumulative incidence of death due to infection at 12 months (considering liver transplantation as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-IFN score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the score including MELD and IFN score for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death due to infection of the MELD-IFN composite score to that of the MELD alone, considering LT as a competitive risk</measure>
    <time_frame>12 months</time_frame>
    <description>AUROC of the score including MELD and IFN score for the prediction of the cumulative incidence of death due to infection at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles score to that of the MELD score alone, considering LT as a competitive risk</measure>
    <time_frame>6 months</time_frame>
    <description>AUROC of the score including MELD and microvesicles for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles score with that of the MELD score alone, considering LT as a competitive risk</measure>
    <time_frame>12 months</time_frame>
    <description>AUROC of the score including MELD and microvesicles for the prediction of the cumulative incidence of death due to infection at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the performance of MELD-microvesicles-IFN, MELD-microvesicles and MELD-IFN versus MELD alone to predict cirrhosis progression.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to CHC status at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consider whether the difference between the prognostic performance of the composite MELD-microvesicles-IFN score and the MELD alone is associated with CHC status at the inclusion</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to CHC status at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate whether the difference between the prognostic performance of the composite MELD-microvesicles-IFN score and the MELD alone could be explained by transplants performed outside MELD</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to whether or not the transplantation was performed on the basis of the MELD</description>
  </secondary_outcome>
  <enrollment type="Actual">335</enrollment>
  <condition>Cirrhosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged over 18 and under 90 with stable Child B or C cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 90 years&#xD;
&#xD;
          -  Child-Pugh B or Child-Pugh C cirrhosis diagnosed on the basis of one or several of the&#xD;
             following elements :&#xD;
&#xD;
               -  Liver Biopsy&#xD;
&#xD;
               -  Liver stiffness&gt;15kPa measured by Fibroscan&#xD;
&#xD;
               -  Combination of clinical, laboratory and imaging criteria characteristic of&#xD;
                  cirrhosis (association of signs of portal hypertension, liver failure and&#xD;
                  abnormal liver morphology in a patient with at least one cause of cirrhosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute renal failure (increase in serum creatinin level by more than 1.5 times the&#xD;
             baseline value or by more than 26 μmol/l from the baseline value) within 15 days&#xD;
             before inclusion&#xD;
&#xD;
          -  Bacterial infection proven or highly suspected on the basis of clinical-laboratory&#xD;
             features within 15 days of inclusion&#xD;
&#xD;
          -  Digestive bleeding within 15 days before inclusion&#xD;
&#xD;
          -  Alcoholic hepatitis in the previous month&#xD;
&#xD;
          -  History of porto-systemic shunt or liver transplant&#xD;
&#xD;
          -  Primary sclerosing cholangitis&#xD;
&#xD;
          -  Primary biliary cirrhosis&#xD;
&#xD;
          -  Budd-Chiari Syndrome&#xD;
&#xD;
          -  Hepatocellular carcinoma outside the Milan criteria contraindicating transplantation&#xD;
&#xD;
          -  Active extrahepatic neoplasia&#xD;
&#xD;
          -  HIV or known immune deficiency or immunosuppressive treatment&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Protected populations: persons under guardianship or curatorship&#xD;
&#xD;
          -  Patient not affiliated to social security&#xD;
&#xD;
          -  Patient who did not signed consent&#xD;
&#xD;
          -  Ongoing participation in an intervention research whose protocol could, according to&#xD;
             the literature, modify the release of hepatocyte microvesicles or the IFN score&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel WEISS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaujon hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié Salpêtrière hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Fontaine hospital</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foch hospital</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Outcome prognostication</keyword>
  <keyword>Microvesicle</keyword>
  <keyword>Monocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03837444
org study id: D20180152
nct id: NCT03837444
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
Chronic liver diseases related to viral hepatitis, metabolic syndrome or excessive alcohol
      consumption can evolve towards cirrhosis. Cirrhosis is responsible for 170 000 deaths per
      year in Europe. Initially asymptomatic and called "compensated" it can become "decompensated"
      with the developement of acute complications such as infections, ascites or variceal
      bleeding. The transition from compensated to decompensated cirrhosis is associated with a
      reduction in survival from 95 to 55% at 1 year.

      The only curative treatment for cirrhosis is liver transplantation (LT). Liver transplants
      are allocated according to the severity of the patients. Despite a modest prognostic value
      (area under the ROC curve = 0.7 to predict the risk of death), graft allocation is based on
      the MELD (Model for End-Stage Liver Disease) score including INR, bilirubin and serum
      creatinine. In 2014, 11.5% of registered patients died on the liver transplant waiting list,
      illustrating the need for biomarkers that predict death and improve MELD-based prediction.

      Microvesicles are membrane vesicles released in extracellular space during cell activation or
      apoptosis. Our team showed that circulating levels of hepatocyte microvesicles increase with
      the severity of cirrhosis and predict survival at 6 months independently of MELD score in a
      cohort of 242 patients with cirrhosis.

      Type 1 interferons (IFN-1) are mediators of inflammation, which is excessively activated in
      cirrhosis. Our team has shown that a gene signature (IFN score) measured in the immune cells
      of 101 patients with cirrhosis is able to predict 6 month-survival independently of the MELD
      score.

      Thus, the investigators hypothesize that a composite score combining the level of circulating
      hepatocyte microvesicles, the IFN score and the MELD score could improve the prediction of
      survival in patients with severe cirrhosis.

      The aim of this study is to compare the prognostic performance for the cumulative incidence
      of death at 6 months of a composite score including MELD, hepatocyte microvesicle level and
      IFN score with that of the MELD score alone, in patients with Child B or C cirrhosis,
      considering liver transplantation as a competitive risk.

      To address this question, peripheral blood from 335 patients with Child B or C cirrhosis will
      be obtained and hepatocyte microvesicle levels and IFN score will be measured using
      ELISA/filtration and Real Time-quantitative PCR.
Natural history of cirrhosis

      Cirrhosis is the end stage form of chronic liver disease. It is estimated that 200,000 to
      500,000 people in France have cirrhosis. Cirrhosis is responsible for more than 170,000
      deaths per year in Europe.

      The main causes of cirrhosis include excessive alcohol consumption, the leading cause in
      Europe, and chronic viral hepatitis B and C, which are the leading causes in Asia and Africa.
      In addition, the current epidemic of obesity and type 2 diabetes worldwide has led to a sharp
      increase in the incidence of non-alcoholic steatohepatitis associated with metabolic
      syndrome, particularly in North America.

      Cirrhosis is defined histologically as a diffuse alteration in the architecture of the liver
      by annular fibrosis associated with regeneration nodules. With the emergence of non-invasive
      tests allowing fibrosis measurement, cirrhosis is now considered highly probable when the
      liver elasticity measured by Fibroscan® is > 15 kPa.

      Patients with cirrhosis may be perfectly asymptomatic and have normal liver function. In this
      case, the Child-Pugh score, which rates the severity of cirrhosis, is "A". However, the
      severity of cirrhosis may increase, resulting in the development of signs of liver failure,
      such as jaundice, decreased coagulation factors and hypoalbuminemia, and/or ascites or
      hepatic encephalopathy. Cirrhosis is then classified as Child-Pugh B or C.

      The progression of cirrhosis involves various processes: on the one hand, a slow and
      continuous worsening associated with the persistence of hepatic aggression by one or more
      causal agents (alcohol and/or metabolic syndrome and/or virus) and on the other hand, rapid
      worsening occurring with acute complications of the disease such as variceal bleeding or
      bacterial infections. Indeed, cirrhosis is associated with major alterations in innate
      immunity that promote severe bacterial infections, which can lead to organ failure. Such a
      complication represents a turning point in the natural history of cirrhosis since the
      transition from compensated to decompensated cirrhosis is associated with a reduction in
      1-year survival from 95 to 60%. When these complications are associated with organ failure,
      short term mortality is dramatically increased with one-third of patients dying within one
      month. The association of acute decompensation of cirrhosis with one or more organ failures
      has recently been defined as a new syndrome named Acute-on-Chronic Liver Failure (ACLF).

      The only curative treatment for cirrhosis is liver transplantation (LT). However, each year,
      between 10 and 15% of patients on the French liver transplant waiting list cannot access
      transplant and die prematurely from an acute complication of cirrhosis. In addition, many
      patients die before they are even put on the transplant waiting list, as evidenced by the
      results of a recent French multicenter study showing that the 6-month mortality rate for
      patients with decompensated cirrhosis, Child C, remains equal to 25%[8].

      Predicting of the outcome is therefore a major challenge in the management of cirrhotic
      patients.

      Prediction of the outcome of patients with cirrhosis: clinical scores.

      Currently, prediction of the outcome of cirrhotic patients is based on the MELD (Model for
      End-Stage Liver Disease) score. MELD score includes three objective laboratory criteria (INR,
      serum bilirubin and serum creatinine). It was established in 2000 in an American cohort to
      predict the risk of death at 3 months after TIPS placement (Transjugular Intrahepatic
      Portosystemic Shunt). Its use was very quickly extended to the prediction 3-month survival of
      cirrhotic patients on the transplant waiting list. Since 2007, in France, graft allocation
      has been based on the MELD score, with patients with the highest score being transplanted
      first.

      Since that time, the predictive value of MELD has been studied in large cohorts, showing that
      MELD's performance in predicting death is modest, with areas under the ROC curves (AUROC)
      ranging from 0.64 to 0.72[3, 7, 19, 20]. In 2014, 7 years after the introduction of the MELD
      score, it was found that 11.5% of patients on the liver transplant waiting list still died
      before they could be transplanted. These data illustrate the need to improve our ability to
      predict death of patients with advanced cirrhosis.

      In this perspective, some authors have tried to improve the MELD score by adding one or more
      variables, such as serum sodium (MELD-Na=MELD-Na-[0.025×MELD× (140 - Na)] + 140). The
      contribution of these modified MELD scores was not considered sufficient to promote their use
      in clinical practice, leaving the objective of improving MELD unmet.

      Prediction of the outcome of patients with cirrhosis: novel biomarkers

      Beside clinical scores, some biomarkers look promising. Indeed, as part of the close
      collaboration between the clinical departments of Beaujon Hospital (Hepatology and
      Anesthesia-Resuscitation) and the Inserm teams (Dr E Weiss, Dr R Moreau, Inserm U1149, Centre
      de recherche sur l'inflammation, Paris) and Pr PE Rautou, Dr C Boulanger, Inserm U970 ;
      Centre de recherche cardiovasculaire, Paris), two types of biomarkers have recently been
      identified that predict the survival of patients with cirrhosis.

      Microvesicles are vesicles released into the extracellular medium during cell activation or
      apoptosis, two phenomena strongly involved in cirrhosis. The Inserm U970 team (Pr PE Rautou,
      Dr C Boulanger) showed in 2012 that the circulating concentrations of hepatocyte
      microvesicles increase with the severity of cirrhosis. In addition, microvesicles in patients
      with child B or C cirrhosis promote portal hypertension by inducing arterial hyporeactivity
      to vasoconstrictive agents. Based on these results, a prospective study including 242
      patients with cirrhosis showed that circulating concentrations of hepatocyte microvesicles
      are able to predict the survival at 6 months of patients with cirrhosis independently of the
      MELD score.

      The susceptibility of cirrhotic patients to severe infections is related to abnormalities in
      their innate immune response and in particular to the occurrence of an excessive inflammatory
      response, responsible for organ failure. Type 1 interferons (IFN 1) are inflammatory
      mediators whose impact on the prognosis of sepsis could be harmful. To determine whether type
      1 IFN pathway activity was involved in the innate immune response deregulation and in the
      susceptibility to sepsis of patients with cirrhosis, the Inserm U1149 team measured, using
      Real-Time quantitative PCR, a gene signature (IFN score) reflecting the activation of this
      pathway in the immune cells of 99 patients with decompensated cirrhosis hospitalized at the
      liver department at Beaujon Hospital. The investigators have thus shown that the IFN score is
      able to predict the risk of death of cirrhotic patients independently of the MELD score with
      AUROC equal to 0.79 (0.7 for MELD).

      It should be noted that these two biomarkers (hepatocyte microvesicles and IFN score) reflect
      different and complementary pathophysiological processes: hepatocyte microvesicles reflect
      persistent liver injury while IFN score reflects innate immune response. It should also be
      noted that these biomarkers, protected by two international patents (EP121528133.5 and
      EP2016/077129) can be measured on peripheral blood using simple and readily available
      techniques (ELISA/filtration, qPCR).

      Hypotheses

      In this project, the investigators hypothesize that prediction of death of patients with
      advanced cirrhosis (Child-Pugh B or C) by a composite score combining circulating
      concentrations of hepatocyte microvesicles, IFN score and MELD score will be better than that
      assessed using the MELD score alone.

      This composite score will help physicians to judge the emergency of liver transplantation and
      thus to refine criteria for the allocation of liver transplants. This composite score may
      also identify a patient population at particular risk of death that should be subjected to
      increased surveillance while waiting for liver transplantation. Through these two approaches
      (better prioritization of patients for liver transplantation and increased monitoring of
      high-risk patients), this new composite score will reduce mortality in cirrhosis patients
      waiting for liver transplantation.

      Finally, new therapeutic approaches to improve survival of patients with severe cirrhosis
      awaiting liver transplantation (e. g. by reducing the occurrence of complications) are
      regularly tested. The composite score the investigators propose could also be used as a
      "companion" to monitor the effectiveness of these new treatments.

      Population

      Patients with Child-Pugh B or C cirrhosis (proven by liver biopsy, by non invasive method of
      fibrosis quantification or by a combination of clinical, biological and radiological signs,
      see above) will be included during a two-year period.

      Patients will be included during follow-up outpatient visits in hepatology or during
      scheduled hospitalization for example for digestive endoscopy to screen signs of portal
      hypertension or for ascites removal. They will therefore be in a stable condition.

      Presence of acute events or events that may modify the risk of death or liver
      transplantation, and/or the inflammatory response or release of microvesicles will be among
      non-inclusion criteria (see above).

      Biomarker measurements

      After informed consent, fifteen to twenty milliliters of peripheral venous blood (3 EDTA
      tubes and 3 citrate tubes) will be collected from patients participating in the study

      For hepatocyte microvesicles, citrated tubes will be centrifuged twice and then frozen at
      -80°C until analysis.

      For the IFN score, blood contained in the 3 EDTA tubes will be used to isolate Peripheral
      Blood Mononuclear Cells (PBMCs). PBMCs will be lysed to obtain RNA that will be stored at
      -80°C until the IFN score is measured.

      At the end of the 2-year inclusion period, measurements of hepatocyte microvesicles and IFN
      score will be performed for all patients during a 1-year period. Plasma concentrations of
      hepatocyte microvesicles will be determined on platelet-free plasma using ELISA/filtration.
      To measure IFN score, RNA from previously isolated PBMCs will first be reverse transcribed.
      Then, the expression of five mRNAs of interest will be measure to calculate the IFN score.

      Primary endpoint

      The primary endpoint is the area under the ROC curve of the composite score including MELD,
      hepatocyte microvesicle concentration and IFN score for predicting the cumulative incidence
      of death at 6 months (considering liver transplantation as a competitive risk) compared to
      the area under the ROC curve of the MELD score alone.

      Measurement of the primary endpoint will be performed according to the recommendations
      specific for survival analysis in patients with cirrhosis, using a survival analysis that
      considers liver transplantation as a competitive risk. Data from patients who did not die or
      have not been transplanted will be censored at the end of follow-up or on the date of last
      news (if the patient is lost to follow-up) or at the date of termination of participation (in
      the event of termination of participation). Follow-up period will be one year after inclusion
      (maximum 13 months for patients who have been transplanted in the 12th month after
      inclusion). A follow-up visit 6 and 12 months after inclusion will be scheduled. Data on
      possible deaths or transplants will be obtained during this visit, using medical records, or
      following telephone calls to patients or their relatives. For subjects who are lost to
      follow-up, requests will be made to the CépiDc to obtain their vital status. Data concerning
      possible transplants will be obtained via a request for access to the "Cristal" database
      (https://www.sipg.sante.fr) developed by the Agence de la biomédecine.
observational model: Cohort
time perspective: Prospective
measure: Compare the prognostic performance for the cumulative incidence of death at 6 months of a composite score including MELD, hepatocyte microvesicle concentration and IFN score to that of the MELD alone, considering LT as a competitive risk
time frame: 6 months
description: AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting the cumulative incidence of death at 6 months (considering liver transplantation (LT) as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death at 12 months of a composite MELD-microvesicles-IFN score to that of the MELD alone, considering liver transplantation as a competitive risk
time frame: 12 months
description: AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting the cumulative incidence of death at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death post-LT, of the composite MELD-microvesicles-IFN score to that of the MELD alone, in patients with Child B or C cirrhosis transplanted during the 12 months following the inclusion
time frame: One month post LT
description: AUROC of the composite score including MELD, hepatocyte microvesicle and IFN score for predicting survival at 1 month post-LT in patients transplanted within 12 months of their inclusion compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for episodes of "Acute on Chronic Liver Failure", of the composite MELD-microvesicles-IFN score to the MELD score alone, considering LT and death as competitive risks at 6 and 12 months
time frame: 6 months and 12 months
description: AUROC of the composite score for predicting the occurrence of episodes of "Acute on Chronic Liver Failure" at 6 and 12 months of inclusion, considering LT and death as competitive risks compared to the AUROC of the MELD score alone
measure: Determine whether this composite score improves prediction of the cumulative incidence of death of patients with Child B or C cirrhosis, compared to the MELD score alone, using the continuous version of the Net Reclassification Index (NRI)
time frame: 6 months and 12 months
description: NRI measuring the reclassification improvement of the composite score for predicting the cumulative incidence of death at 6 and 12 months in patients with Child B or C cirrhosis compared to the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death of a MELD-microvesicles-IFN score to that of the MELD-Na score, considering LT as a competitive event at 6 and 12 months
time frame: 6 months and 12 months
description: AUROC of the composite score for predicting cumulative incidence of death at 6 and 12 months (considering LT as a competitive risk), compared to the AUROC of the MELD-Na score
measure: Compare the prognostic performance for the cumulative incidence of death of a composite MELD-hepatocyte microvesicles score to that of the MELD alone, considering LT as a competitive risk
time frame: 6 months
description: AUROC of the composite score including MELD and hepatocyte microvesicle for predicting the cumulative incidence of death at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death of a composite MELD-IFN score with that of the MELD score alone, considering liver transplantation as a competitive risk
time frame: 6 months
description: AUROC of the composite score including MELD and IFN score for predicting the cumulative incidence of death at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence death due to infection of the composite MELD-microvesicles-IFN score to that of the MELD alone, considering LT as a competitive risk
time frame: 6 months
description: AUROC of the score including MELD, microvesicles and IFN score for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles-IFN score to that of the MELD alone, considering LT as a competitive risk
time frame: 12 months
description: AUROC of the score including MELD, microvesicles and IFN score for the prediction of the cumulative incidence of death due to infection at 12 months (considering liver transplantation as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-IFN score to that of the MELD alone, considering LT as a competitive risk
time frame: 6 months
description: AUROC of the score including MELD and IFN score for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death due to infection of the MELD-IFN composite score to that of the MELD alone, considering LT as a competitive risk
time frame: 12 months
description: AUROC of the score including MELD and IFN score for the prediction of the cumulative incidence of death due to infection at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles score to that of the MELD score alone, considering LT as a competitive risk
time frame: 6 months
description: AUROC of the score including MELD and microvesicles for the prediction of the cumulative incidence of death due to infection at 6 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the prognostic performance for the cumulative incidence of death due to infection of the composite MELD-microvesicles score with that of the MELD score alone, considering LT as a competitive risk
time frame: 12 months
description: AUROC of the score including MELD and microvesicles for the prediction of the cumulative incidence of death due to infection at 12 months (considering LT as a competitive risk) compared to the AUROC of the MELD score alone
measure: Compare the performance of MELD-microvesicles-IFN, MELD-microvesicles and MELD-IFN versus MELD alone to predict cirrhosis progression.
time frame: 6 and 12 months
description: Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to CHC status at inclusion
measure: Consider whether the difference between the prognostic performance of the composite MELD-microvesicles-IFN score and the MELD alone is associated with CHC status at the inclusion
time frame: 6 and 12 months
description: Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to CHC status at inclusion
measure: Investigate whether the difference between the prognostic performance of the composite MELD-microvesicles-IFN score and the MELD alone could be explained by transplants performed outside MELD
time frame: 6 and 12 months
description: Difference between the prognostic performance of the composite score MELD-microvesicle-IFN and the MELD score alone according to whether or not the transplantation was performed on the basis of the MELD
Plasma and RNA
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 90 Years
healthy volunteers: No
last name: Emmanuel WEISS, MD, PhD
role: Principal Investigator
affiliation: Assistance Publique - Hôpitaux de Paris
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Liver Cirrhosis
mesh term: Fibrosis